CDMO Stock Overview
Avid Bioservices, Inc., a contract development and manufacturing organization, provides process development and current good manufacturing practices (CGMP) clinical and commercial manufacturing services of biologics for the biotechnology and biopharmaceutical industries.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
Avid Bioservices, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$7.32 |
| 52 Week High | US$18.86 |
| 52 Week Low | US$4.07 |
| Beta | 1.62 |
| 1 Month Change | 7.81% |
| 3 Month Change | 8.12% |
| 1 Year Change | -58.64% |
| 3 Year Change | -66.34% |
| 5 Year Change | 60.53% |
| Change since IPO | -62.65% |
Recent News & Updates
Recent updates
There's No Escaping Avid Bioservices, Inc.'s (NASDAQ:CDMO) Muted Revenues Despite A 40% Share Price Rise
Mar 07
We Think Avid Bioservices (NASDAQ:CDMO) Has A Fair Chunk Of Debt
Feb 28There's No Escaping Avid Bioservices, Inc.'s (NASDAQ:CDMO) Muted Revenues Despite A 39% Share Price Rise
Dec 28Does Avid Bioservices (NASDAQ:CDMO) Have A Healthy Balance Sheet?
Nov 10Calculating The Intrinsic Value Of Avid Bioservices, Inc. (NASDAQ:CDMO)
Oct 15Time To Worry? Analysts Are Downgrading Their Avid Bioservices, Inc. (NASDAQ:CDMO) Outlook
Jun 23Is Avid Bioservices (NASDAQ:CDMO) Using Too Much Debt?
Jun 12Little Excitement Around Avid Bioservices, Inc.'s (NASDAQ:CDMO) Earnings As Shares Take 26% Pounding
May 21Are Investors Undervaluing Avid Bioservices, Inc. (NASDAQ:CDMO) By 49%?
May 12Does Avid Bioservices (NASDAQ:CDMO) Have A Healthy Balance Sheet?
Mar 13Here's Why Avid Bioservices (NASDAQ:CDMO) Has A Meaningful Debt Burden
Nov 10Avid Bioservices GAAP EPS of $0.02 beats by $0.01, revenue of $36.7M beats by $3.26M
Sep 06Laughing Water Capital - Avid Bioservices: Not A Binary Bet But A Real Business
Jul 27Avid Bioservices GAAP EPS of $1.65 beats by $1.65, revenue of $31M beats by $2.04M
Jun 29Avid Bioservices (NASDAQ:CDMO) Seems To Use Debt Quite Sensibly
May 30Shareholder Returns
| CDMO | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 12.3% | 0.4% | 1.0% |
| 1Y | -58.6% | 0.9% | 21.9% |
Price Volatility
| CDMO volatility | |
|---|---|
| CDMO Average Weekly Movement | 13.9% |
| Biotechs Industry Average Movement | 11.6% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.8% |
| 10% least volatile stocks in US Market | 3.0% |
Volatility Over Time: CDMO's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1981 | 365 | Nick Green | www.avidbio.com |
Avid Bioservices, Inc., a contract development and manufacturing organization, provides process development and current good manufacturing practices (CGMP) clinical and commercial manufacturing services of biologics for the biotechnology and biopharmaceutical industries. The company offers various services, including clinical and commercial drug substance manufacturing, bulk packaging, release and stability testing, and regulatory submission and support. It also provides various process development services, such as upstream and downstream development and optimization, analytical methods development, cell line development, testing, and characterization.
Avid Bioservices, Inc. Fundamentals Summary
| CDMO fundamental statistics | |
|---|---|
| Market cap | US$464.67m |
| Earnings (TTM) | -US$17.68m |
| Revenue (TTM) | US$136.74m |
3.4x
P/S Ratio-26.3x
P/E RatioIs CDMO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CDMO income statement (TTM) | |
|---|---|
| Revenue | US$136.74m |
| Cost of Revenue | US$126.53m |
| Gross Profit | US$10.21m |
| Other Expenses | US$27.89m |
| Earnings | -US$17.68m |
Last Reported Earnings
Jan 31, 2024
Next Earnings Date
Apr 29, 2024
| Earnings per share (EPS) | -0.28 |
| Gross Margin | 7.47% |
| Net Profit Margin | -12.93% |
| Debt/Equity Ratio | 78.5% |
How did CDMO perform over the long term?
See historical performance and comparison